Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab + Sorafenib in Advanced HCC
NCT02988440Phase 1Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Primary completion
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 8
01
Overview
Phase 1, open-label, single-arm trial of spartalizumab in hepatocellular carcinoma (HCC), sponsored by Novartis. Primary endpoints: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Incidence of Dose Limiting Toxicities and 3 more. Started Apr 2017; status: completed.
02
Drugs
spartalizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02988440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988440.